Prevention of hip fractures by correcting calcium and vitamin D insufficiencies in elderly people.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this controlled clinical trial publication.

A great deal has been learned in recent years about the risk factors for hip fracture, the pathophysiology of this fracture, and the prediction of fracture risk, particularly through bone mass measurements on the hip and biochemical evaluations of parathyroid and vitamin D status.

The two main determinants of hip fractures are falls and bone loss leading to an intrinsic femoral fragility.

Who Took Part

The study group was 446 women.

The age groups tagged for this paper are older adults, both men and women.

How the Study Was Run

The design is described as placebo-controlled and parallel-group.

Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

What Was Measured

A great deal has been learned in recent years about the risk factors for hip fracture, the pathophysiology of this fracture, and the prediction of fracture risk, particularly through bone mass measurements on the hip and biochemical evaluations of parathyroid and vitamin D status.

PubMed files the paper under topics including Calcium, Hip Fractures, Hyperparathyroidism, Vitamin D and Vitamin D Deficiency.

What This Means in Plain Language

The paper is a placebo-controlled and parallel-group study of Vitamin D, K2, Magnesium and Zinc in 446 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 1996 (Scandinavian journal of rheumatology. Supplement), a journal based in Norway.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.